|
Monday, 07 March 2011 |
|
Delscience.com will provide you with comprehensive analysis of particular niches of the biopharmaceutical sector. Our news and reports - multiclient and /or ad hoc - will allow you to know competing products, identify development opportunities, assess potential partners or examine competitors' capabilities. At the present time, information and intelligence services are focused on nanomedicine and drug delivery. If you are interested in developing or investing in drug delivery technologies, please register above to receive email updates on future services on Delscience.com. Using DelScience's services, you will gain essential information that will improve your strategic decision making process. If you would like to know how DelScience may be of use to your company or research group, please go to Contact us section or email us. DelScience's team |
|
|
Wednesday, 23 February 2011 |
|
Delcath Systems, Inc announced that the Company has received a "refusal to file" letter from the Food and Drug Administration (FDA) for the New Drug Application (NDA) for its proprietary chemosaturation system used in the treatment of patients with metastatic melanoma in the liver through the percutaneous intra-arterial administration of melphalan hydrochloride. |
|
|
Thursday, 17 February 2011 |
|
TransPharma Medical Ltd. announced the completion of a Phase 1b trial of ViaDor-GLP1 agonist, which is being developed for the treatment of diabetes mellitus type II. |
|
|
Monday, 17 January 2011 |
|
Micell Technologies(TM), Inc. announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. This clinical investigation is being conducted to support CE Mark approval of the company’s MiStent(TM) Drug-Eluting Coronary Stent System (MiStent DES). |
|
|
Thursday, 03 February 2011 |
|
The Debiopharm Group and Marina Biotech, Inc. announced that they entered into an exclusive agreement concerning the development and commercialization of Marina Biotech's pre-clinical program in bladder cancer. |
|
|
Monday, 31 January 2011 |
|
Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application (IND) from the US Food and Drug Administration (FDA) for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer. |
|
|
